远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00512 远大医药

休市中 11-22 16:08:13

4.340

-0.110

-2.47%

最高4.500	最低4.300	成交量282.50万
今开4.500	昨收4.450	日振幅4.49%
总市值154.05亿	流通市值154.05亿	总股本35.50亿
成交额1,236万	换手率0.08%	流通股本35.50亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00512","market":"HK","secType":"STK","nameCN":"远大医药","latestPrice":4.34,"timestamp":1732262893013,"preClose":4.45,"halted":0,"volume":2825000,"delay":0,"floatShares":3549571148,"shares":3549571148,"eps":0.535954,"marketStatus":"休市中","marketStatusCode":7,"change":-0.11,"latestTime":"11-22 16:08:13","open":4.5,"high":4.5,"low":4.3,"amount":12364280,"amplitude":0.044944,"askPrice":4.34,"askSize":4000,"bidPrice":4.33,"bidSize":20500,"shortable":3,"etf":0,"ttmEps":0.689282,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"listingDate":819302400000,"adjPreClose":4.45,"dividendRate":0.059908,"openAndCloseTimeList":[[1732239000000,1732248000000],[1732251600000,1732262400000]],"volumeRatio":0.9629478133415141,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00512","defaultTab":"news","newsList":[{"id":"2484165526","title":"远大医药11月20日获主力加仓481万元 环比增加23950.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484165526","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484165526?lang=zh_cn&edition=full","pubTime":"2024-11-20 16:17","pubTimestamp":1732090621,"startTime":"0","endTime":"0","summary":"11月20日, 远大医药股价跌1.72%，报收4.56元，成交金额2376万元，换手率0.15%，振幅3.02%，量比1.72。远大医药今日主力资金净流入481万元，上一交易日主力净流入2万元，今日环比增加23950.00%。该股近5个交易日下跌4.41%，主力资金累计净流入318万元；近20日主力资金累计净流出346万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120161745a247f717&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120161745a247f717&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2484958895","title":"南向资金11月18日净买入远大医药59.55万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2484958895","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484958895?lang=zh_cn&edition=full","pubTime":"2024-11-19 09:30","pubTimestamp":1731979807,"startTime":"0","endTime":"0","summary":"11月18日, 南向资金增持远大医药59.55万股，连续3日增持。截止当日收盘，港股通共持有远大医药35241.11万股，占流通股9.92%。远大医药近5个交易日下跌1.71%，港股通累计增持75.40万股；近20个交易日下跌1.50%，港股通累计增持683.35万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119093033abcdceeb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119093033abcdceeb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2483323703","title":"远大医药签署2024分销协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2483323703","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483323703?lang=zh_cn&edition=full","pubTime":"2024-11-15 18:38","pubTimestamp":1731667111,"startTime":"0","endTime":"0","summary":"财中社11月15日电远大医药（00512）发布公告，宣布与SirtexMedical签订了2024分销协议。根据协议，北京普尔伟业与成都普尔伟业将作为SirtexMedical在中国的独家经销商，购买固定数量的产品进行转售。2024分销协议的有效期为自签署之日起至2025年11月14日，期间北京普尔伟业将最多购买800套产品，而成都普尔伟业将最多购买200套产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411153241197385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","00512"],"gpt_icon":0},{"id":"2481088605","title":"【百强透视】眼科药物再迎利好！对远大医药有何影响？","url":"https://stock-news.laohu8.com/highlight/detail?id=2481088605","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481088605?lang=zh_cn&edition=full","pubTime":"2024-11-05 20:17","pubTimestamp":1730809069,"startTime":"0","endTime":"0","summary":"11月4日，远大医药（00512.HK）宣告称，全球创新眼科药物GPN00833完成国内III期临床研究并达到了临床终点。而在11月5日，远大医药的股价上涨了2.41%。结合普涨的市场来看，远大医药的股价反应比较平淡。","market":"us","thumbnail":"https://images.finet.hk/photoLib/title/202411_1/c1f0f609-0b59-48e6-8069-35b3dc3644d5.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202411_1/c1f0f609-0b59-48e6-8069-35b3dc3644d5.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/672a0ced53243c03f8d58e2c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2481052396","title":"远大医药11月05日获主力加仓304万元 环比增加700.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481052396","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481052396?lang=zh_cn&edition=full","pubTime":"2024-11-05 16:15","pubTimestamp":1730794549,"startTime":"0","endTime":"0","summary":"11月05日, 远大医药股价涨2.41%，报收4.67元，成交金额1357万元，换手率0.08%，振幅2.85%，量比1.28。远大医药今日主力资金净流入304万元，上一交易日主力净流入38万元，今日环比增加700.00%。该股近5个交易日上涨0.86%，主力资金累计净流入278万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流出119万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105161612a217c60d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105161612a217c60d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00512"],"gpt_icon":0},{"id":"2481510766","title":"远大医药：全球创新激素纳米混悬滴眼液III期临床成功达到临床终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2481510766","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481510766?lang=zh_cn&edition=full","pubTime":"2024-11-05 13:35","pubTimestamp":1730784941,"startTime":"0","endTime":"0","summary":"近日，远大医药发布公告称，用于眼科术后抗炎镇痛的全球创新激素纳米混悬滴眼液GPN00833完成了国内III期临床研究并成功达到了临床终点。根据公告，GPN00833为一款抗炎镇痛类激素纳米混悬滴眼液，其主要活性成分丙酸氯倍他索是一种强效的糖皮质激素，具有高效的局部抗炎活性和较强的毛细血管收缩作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411053229555992.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00512","III","BK4134","BK1191"],"gpt_icon":0},{"id":"2481591927","title":"南向资金11月4日净买入远大医药55.80万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2481591927","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481591927?lang=zh_cn&edition=full","pubTime":"2024-11-05 09:30","pubTimestamp":1730770208,"startTime":"0","endTime":"0","summary":"11月4日, 南向资金增持远大医药55.80万股，连续5日增持。截止当日收盘，港股通共持有远大医药34939.96万股，占流通股9.84%。远大医药近5个交易日下跌1.72%，港股通累计增持313.80万股；近20个交易日下跌12.31%，港股通累计增持960.75万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105093041a2165cc2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105093041a2165cc2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2481595485","title":"金十数据整理：每日港股市场要闻速递（11月5日 周二）","url":"https://stock-news.laohu8.com/highlight/detail?id=2481595485","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481595485?lang=zh_cn&edition=full","pubTime":"2024-11-05 09:07","pubTimestamp":1730768857,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["YANG","BK1604","00005","09987","III","LU0359202008.SGD","YUMC","BK1507","BK1610","BK1231","BK1555","BK1233","BK4504","HSBC","BK1523","LU0417516902.SGD","LU0456842615.SGD","BK1240","LU0823426308.USD","LU0650527681.SGD","IE00BGV7N243.SGD","BK1502","01458","HSHD.SI","LU0348735423.USD","LU1023057109.AUD","03383","LU2279701549.SGD","LU0572944931.SGD","BK1521","IE0034224299.USD","HSCEI","LU0327786744.USD","BK1589","07226","LU1515016050.SGD","00512","00123","LU0823426480.USD","LU1481107354.HKD","BK4526","02007","BK1588","HSBA.UK","01918","06158","03301","03143","HSTECH","LU0634319403.HKD"],"gpt_icon":0},{"id":"2481984415","title":"【湾区早参】香港第3季中小企信贷状况略有改善；国内首个低空气象产业集群已在深圳成形","url":"https://stock-news.laohu8.com/highlight/detail?id=2481984415","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481984415?lang=zh_cn&edition=full","pubTime":"2024-11-05 08:27","pubTimestamp":1730766453,"startTime":"0","endTime":"0","summary":"调查显示，中小企信贷状况略有改善。同时，在行业内部对低空气象监测和预报服务等加强统筹管理。","market":"us","thumbnail":"https://static.szfiu.com/news/20230515/ZGJkOWM1Nzk2NTY2M2QxMDEzMTU3MjkwNTIx.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20230515/ZGJkOWM1Nzk2NTY2M2QxMDEzMTU3MjkwNTIx.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947072","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","BK1233","BK1240","03383","LU0823426308.USD","BK1172","00512","BK1507","IE00B29SXL02.USD","LU0348825331.USD","LU0417516902.SGD","LU0650527681.SGD","LU0228659784.USD","LU0823426480.USD","09987","LU0314104364.USD","01128","02007","00123","BK1555","LU2449327464.USD","LU0122376428.USD","LU0251142724.SGD","BK1589","BK1521","LU0742534661.SGD","LU0048573561.USD","LU2279701549.SGD","BK1610","LNG","LU0788109394.HKD","IE00B29SXK94.USD","LU0594300419.USD","BK4144","LU0251131958.USD","BK1191","LU0368265418.SGD","LU0170899867.USD"],"gpt_icon":0},{"id":"2480371906","title":"远大医药(00512)：全球创新激素纳米混悬滴眼液GPN00833国内III期临床成功达到临床终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2480371906","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480371906?lang=zh_cn&edition=full","pubTime":"2024-11-04 17:14","pubTimestamp":1730711694,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月4日，港股科技创新型医药企业远大医药五官科板块眼科方向传来利好：公司用于眼科术后抗炎镇痛的全球创新激素纳米混悬滴眼液GPN00833完成了国内III期临床研究并成功达到了临床终点。海外注册方面，该产品已于2023年3月获得美国FDA批准上市。远大医药表示，本次GPN00833国内III期临床顺利达到临床终点是公司五官科板块眼科方向的又一次重大里程碑进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1206324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK4134","00512","III"],"gpt_icon":0},{"id":"2480371153","title":"远大医药眼科新药III期临床研究达标","url":"https://stock-news.laohu8.com/highlight/detail?id=2480371153","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480371153?lang=zh_cn&edition=full","pubTime":"2024-11-04 17:13","pubTimestamp":1730711580,"startTime":"0","endTime":"0","summary":"财中社11月4日电远大医药 发布公告称，其全球创新眼科药物GPN00833已完成在中国开展的III期临床研究，并成功达到临床终点。该药物用于眼科术后抗炎镇痛，主要活性成分为丙酸氯倍他索，具有高效的局部抗炎活性。此外，GPN00833的安全性和耐受性良好，药代动力学特征符合预期。该产品已于2024年3月获得美国FDA批准上市。公司在五官科领域的产品管线数量位居行业前列，未来将继续加强创新研发，丰富产品线，推动全球化运营布局，以满足临床需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104172833a2148833&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104172833a2148833&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00512"],"gpt_icon":0},{"id":"2480376402","title":"远大医药(00512)全球创新眼科药物 GPN00833 完成国内 III 期临床研究并达到了临床终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2480376402","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480376402?lang=zh_cn&edition=full","pubTime":"2024-11-04 16:53","pubTimestamp":1730710431,"startTime":"0","endTime":"0","summary":"智通财经APP讯，远大医药 公布，近日，该集团用于眼科术后抗炎镇痛的激素纳米混悬滴眼液 GPN00833 完成了在中国开展的 III 期临床研究并成功达到了临床终点，是该集团在五官科领域眼科方向的又一次重大里程碑进展。综上分析显示，GPN00833 在治疗白内障术后抗炎镇痛方面疗效显著优于安慰剂组，且安全性良好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1206300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","BK1191","BK1214","00833","BK4134","III"],"gpt_icon":0},{"id":"2480376044","title":"远大医药(00512.HK)创新眼科药物完成中国III期临床并达到临床终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2480376044","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480376044?lang=zh_cn&edition=full","pubTime":"2024-11-04 16:53","pubTimestamp":1730710380,"startTime":"0","endTime":"0","summary":"远大医药公布，集团用于眼科术后抗炎镇痛的激素纳米混悬滴眼液GPN00833完成了在中国开展的III期临床研究并达到临床终点。本研究的主要临床终点为白内障手术后第8天到15天前房细胞计数为零的患者百分比，次要临床终点为术后第4天到第15天眼部疼痛等级为零的患者百分比。(港股报价延迟最少十五分钟。沽空资料截至 2024-11-04 16:25。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240508115941767_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240508115941767_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1393943/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2479429116","title":"远大医药10月29日主力资金流出41万元 连续5日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2479429116","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479429116?lang=zh_cn&edition=full","pubTime":"2024-10-29 16:16","pubTimestamp":1730189808,"startTime":"0","endTime":"0","summary":"10月29日, 远大医药股价涨0.22%，报收4.65元，成交金额830万元，换手率0.05%，振幅2.80%，量比0.61。远大医药今日主力资金净流出41万元，连续5日净流出，上一交易日主力净流出311万元，今日环比减少86.82%。该股近5个交易日下跌0.42%，主力资金累计净流出808万元，其中3个交易日为股价上涨时净流出；近20日主力资金累计净流入818万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029161723ab7e1576&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029161723ab7e1576&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2478844677","title":"远大医药10月25日主力资金流出188万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2478844677","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478844677?lang=zh_cn&edition=full","pubTime":"2024-10-25 16:16","pubTimestamp":1729844213,"startTime":"0","endTime":"0","summary":"10月25日, 远大医药股价涨0.64%，报收4.72元，成交金额1285万元，换手率0.08%，振幅1.92%，量比0.88。远大医药今日主力资金净流出188万元，连续3日净流出，上一交易日主力净流出223万元，今日环比减少15.70%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为53.85%，平均跌幅为0.99%。该股主力净额占比0.01%，港股市场排名2456/2643。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025161729ab72ebfb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025161729ab72ebfb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2477577156","title":"远大医药10月24日遭主力抛售223万元 环比增加374.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477577156","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477577156?lang=zh_cn&edition=full","pubTime":"2024-10-24 16:16","pubTimestamp":1729757819,"startTime":"0","endTime":"0","summary":"10月24日, 远大医药股价跌1.26%，报收4.69元，成交金额1528万元，换手率0.09%，振幅4.63%，量比0.99。远大医药今日主力资金净流出223万元，上一交易日主力净流出47万元，今日环比增加374.47%。该股近5个交易日上涨2.85%，主力资金累计净流出306万元；近20日主力资金累计净流入1353万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241024161733a1e649bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241024161733a1e649bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2477833749","title":"远大医药可调节颅内取栓支架获批上市 持续夯实心脑血管精准介入诊疗板块布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2477833749","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477833749?lang=zh_cn&edition=full","pubTime":"2024-10-22 21:39","pubTimestamp":1729604380,"startTime":"0","endTime":"0","summary":"本报讯（记者张敏）10月22日，远大医药发布公告称，其用于治疗急性缺血性卒中的可调节颅内取栓支架产品“鸬鹚”日前已获药监局颁发医疗器械注册证书。此次产品获批是远大医药在神经介入板块产品布局的又一突破性进展。脑卒中可分为缺血性脑卒中和出血性脑卒中两种类型。根据《中国急性缺血性卒中诊治指南2023》，急性缺血性卒中（AIS，又称脑梗死）是最常见的卒中类型。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202410223213980524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2477980011","title":"【港股通】远大医药(00512)用于治疗急性缺血性卒中的可调节颅内取栓支架产品获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2477980011","media":"金吾财讯","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477980011?lang=zh_cn&edition=full","pubTime":"2024-10-22 17:19","pubTimestamp":1729588775,"startTime":"0","endTime":"0","summary":"金吾财讯 | 远大医药(00512)公告，集团与联营公司南京凯尼特医疗技术有限公司共同研发的用于治疗急性缺血性卒中的可调节颅内取栓支架产品(“鸬鹚”)近日获得国家药监局颁发医疗器械注册证书。鸬鹚是首款国产的可调节颅内取栓支架产品。该款支架采用圆丝编织结构设计，可在体外进行手动调控至理想直径以匹配目标血管，同时支架植入过程中全程可视、全程显影，能够更好的辅助术者根据血栓部位与总长度，来调节支架以更好的适应闭塞血管，实现更高的血管再通率。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210510/ODZjYTYwNTJhNDNjMjgyMWJhNDY2ZTQzMDQ0NzUzMTY1Mjk2OTkx.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210510/ODZjYTYwNTJhNDNjMjgyMWJhNDY2ZTQzMDQ0NzUzMTY1Mjk2OTkx.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1946296","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSCEI","00512","YANG","HSTECH","BK1191"],"gpt_icon":0},{"id":"2477800587","title":"持续推进高端医疗器械研发，远大医药(00512)首款国产可调节颅内取栓支架获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2477800587","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477800587?lang=zh_cn&edition=full","pubTime":"2024-10-22 17:08","pubTimestamp":1729588117,"startTime":"0","endTime":"0","summary":"智通财经APP讯，10月22日，港股科技创新型医药企业远大医药 发布公告称，其用于治疗急性缺血性卒中的可调节颅内取栓支架产品“鸬鹚”日前已获药监局颁发医疗器械注册证书。鸬鹚是我国首款国产的可调节颅内取栓支架产品，此次产品获批是远大医药在神经介入板块产品布局的又一突破性进展。该研究结果表明，鸬鹚用于AIS患者的血管内治疗是安全和有效的。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1197419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","BK1583","159883","BK1222","BK1574","BK1191","09996","09997","BK1100"],"gpt_icon":0},{"id":"2477795807","title":"远大医药(00512.HK)用于治疗脑梗死产品获发注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2477795807","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477795807?lang=zh_cn&edition=full","pubTime":"2024-10-22 17:00","pubTimestamp":1729587600,"startTime":"0","endTime":"0","summary":"远大医药(00512.HK) 公布，集团与联营公司共同研发，用于治疗急性缺血性卒中(又称脑梗死)的可调节颅内取栓支架产品(Luci)近日获得药监局颁发医疗器械注册证书。公司指，Luci是首款内地出产的可调节颅内取栓支架产品，可以在体外进行手动调控至理想直径以匹配目标血管，实现更高的血管再通率。(vc/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-10-22 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240508115941767_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240508115941767_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1390106/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","00512"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinagrandpharm.com","stockEarnings":[{"period":"1week","weight":-0.0766},{"period":"1month","weight":-0.0863},{"period":"3month","weight":0.0333},{"period":"6month","weight":-0.0996},{"period":"1year","weight":-0.0667},{"period":"ytd","weight":0.0611}],"compareEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":-0.0737},{"period":"3month","weight":0.0919},{"period":"6month","weight":0.0334},{"period":"1year","weight":0.0736},{"period":"ytd","weight":0.128}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"远大医药健康控股有限公司是一家主要从事制造及销售医药制剂及医疗器械的香港投资控股公司。该公司主要从事制造及销售医药制剂及医疗器械、生物技术产品及营养产品、精品原料药和其他产品。该公司的主要产品涵盖抗肿瘤、心血管急救制剂及高端心脑血管介入医疗器械、抗病毒抗感染、呼吸及五官科以及生物健康产品和精品原料药。","yearOnYearQuotes":[{"month":1,"riseRate":0.482759,"avgChangeRate":0.094346},{"month":2,"riseRate":0.689655,"avgChangeRate":0.105408},{"month":3,"riseRate":0.37931,"avgChangeRate":0.012932},{"month":4,"riseRate":0.62069,"avgChangeRate":0.018409},{"month":5,"riseRate":0.448276,"avgChangeRate":0.071029},{"month":6,"riseRate":0.344828,"avgChangeRate":-0.050119},{"month":7,"riseRate":0.37931,"avgChangeRate":-0.015206},{"month":8,"riseRate":0.37931,"avgChangeRate":0.00388},{"month":9,"riseRate":0.482759,"avgChangeRate":-0.037799},{"month":10,"riseRate":0.517241,"avgChangeRate":-0.014247},{"month":11,"riseRate":0.517241,"avgChangeRate":0.086737},{"month":12,"riseRate":0.5,"avgChangeRate":-0.008312}],"exchange":"SEHK","name":"远大医药","nameEN":"GRAND PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"远大医药,00512,远大医药股票,远大医药股票老虎,远大医药股票老虎国际,远大医药行情,远大医药股票行情,远大医药股价,远大医药股市,远大医药股票价格,远大医药股票交易,远大医药股票购买,远大医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}